Systemic 红斑狼疮 Erythematosus

澳门第一赌城在线娱乐对狼疮社区和推进狼疮科学认识的承诺

Our vision for systemic 红斑狼疮 erythematosus

系统性红斑狼疮(SLE)是一种慢性免疫驱动疾病,在这种疾病中,身体的免疫系统攻击身体任何部位的健康组织.1 每个人的经历都不一样,会导致各种各样的衰弱症状, 包括皮疹, 关节疼痛, 肿胀和发烧.2 治疗SLE的新药很少,而且对身体、情绪和
socio-economic burden remains high for people living with the disease.3,4

澳门第一赌城在线娱乐的研究人员正在努力解开免疫系统的科学,以解决狼疮患者的重大未满足需求. 通过强调SLE患者的经验和调查这种复杂疾病的潜在驱动因素, 澳门第一赌城在线娱乐的目标是为狼疮社区带来科学进步,挑战他们长期以来不得不接受的界限.
 

病人的肖像

红斑狼疮 affects each person differently and can be unpredictable. 听到与系统性红斑狼疮(SLE)的人如何疾病已经影响了他们的生活,因为诊断, and their hope for scientific advancements in the field.


Addressing unmet needs in the 红斑狼疮 community

SLE is more common among those of African, Asian or Hispanic ethnicities.6 It is also estimated that 90 percent of people diagnosed with SLE are women.1

需要新的治疗方法来解决那些狼疮患者及其医疗保健专业人员面临的重大未满足的医疗需求. Patients still often have inadequate disease control, poor health-related quality of life outcomes and related health conditions. Many people with SLE rely on prolonged use of oral corticosteroids, 哪一种药物有助于解决疾病活动性增加的问题,但也可能增加器官损伤和其他重大副作用的风险.3,7,8,9

处理器官损伤和更严重的疾病特征往往需要更昂贵的护理.10 跨越多个国家, 澳门第一赌城在线娱乐发现早期诊断和治疗对于降低SLE的经济负担至关重要, and can help to reduce the risk of disease progression and flare frequency, protecting from organ damage and improving quality of life.11-15



澳门第一赌城在线娱乐将继续跟随科学,进一步解开澳门第一赌城在线娱乐对SLE等复杂免疫驱动疾病的理解. If we can recognise and address the underlying drivers of disease, we can tackle key areas of unmet need that remain.

Caterina Brindicci Senior Vice President and Global Head of 呼吸 & 免疫学 Late-Stage Development, 澳门第一赌城在线娱乐 R&D、澳门在线赌城娱乐

Unlocking the science of SLE

对于SLE患者来说,免疫系统会不恰当地攻击身体的健康组织.1 SLE disease activity involves B, T和树突状细胞, as well as inflammatory cytokines such as type 1 interferons (IFN-1), IL-6 and B-cell activating factor. Cytokines are molecules that act as immune signallers, 调节沿着免疫途径协调整体免疫反应的过程. This results in an over-activated immune response, 伴随着自身抗体的产生(针对身体自身组织形成的抗体), 会导致伤害, inflammation and long-term organ damage. Up to 60-80% of adults with SLE may have an elevated IFN-1 gene signature, which can be associated with increased disease severity.16-21

By understanding the role key inflammatory cytokines play in that cascade, we can begin to further unlock the complex nature of this challenging disease.


参考文献

1. The 红斑狼疮 Foundation of America. 什么是狼疮? 可在:http://www.红斑狼疮.org/resources/what-is-红斑狼疮. 2023年5月.

2. American College of 风湿病学. 成人系统性红斑狼疮的转诊和治疗指南. 关节炎 & 风湿病学. 1999;42:1785-1796.

3. Mahieu MA,等. A critical review of clinical trials in systemic 红斑狼疮 eythematosus. 红斑狼疮. 2016; 25 (10): 1122-1140 

4. Merrill JT等. 红斑狼疮 community panel proposals for optimising clinical trials: 2018. 狼疮科学医学. 2018;5:E000258

5. Al Sawah S, Daly RP, Foster SA, et al. The caregiver burden in 红斑狼疮: findings from UNVEIL, a national online 红斑狼疮 survey in the United States. 红斑狼疮. 2017年1月,26 (1):54 - 61.

6. Rees F, Doherty M, Grainge MJ, et al. 全球系统性红斑狼疮的发病率和患病率:流行病学研究的系统回顾. 风湿病学. 2017;56(11), pp. 1945-1961.

7. 哈里斯,J,莫兰,E. Editorial: Focus on Systemic 红斑狼疮 Erythematosus. 前面Immunol. 2016;7:400. doi: 10.3389 / fimmu.2016.00400.

8. Samnaliev M, Barut V, Weir S, et al. 英国成人系统性红斑狼疮患者的医疗保健利用和费用:一项真实世界的观察性回顾性队列研究[海报]. Presented at: The European League Against Rheumatism, 欧拉描述, European E-Congress of 风湿病学 2020; 3-6 June 2020. 摘要ID: THU0550.

9. Al Sawah S, Zhang X, Zhu B, et al. 使用皮质类固醇剂量对系统性红斑狼疮发生器官损伤风险的影响——霍普金斯狼疮队列. 狼疮科学医学. 2015;2(1):e000066.

10. Kan HJ, Song X, Johnson BH, et al. Healthcare utilization and costs of systemic 红斑狼疮 erythematosus in Medicaid. 国际生物医学研究中心. doi: 10.1155/2013/808391.

11. Nusbaum J, Mirza I, Shum J, et al. Sex Differences in Systemic 红斑狼疮 Erythematosus: Epidemiology, 临床考虑, 及发病机制. 梅奥临床项目. 2020;95(2):384–394.

12. Hammond ER, Murimi IB, Lin DH, et al. 美国系统性红斑狼疮的医疗保健利用和成本:系统综述[海报]. Presented at: The European League Against Rheumatism, 欧拉描述, European Congress of 风湿病学 2017; 14-17 June 2017. 摘要ID: SAT0227.

13. Murimi I, Dora L, Hong K, et al. 美国系统性红斑狼疮疾病严重程度的医疗保健利用和成本. J Rheumatol. 2020;191187. doi: http://doi.org/10.3899 / jrheum.

14. Hammond E, Freidel H, Garal-Pantaler E, et al. 保健资源使用(hru)和医疗费用分析作为系统性红斑狼疮(sle)疾病严重程度的函数:对德国疾病基金索赔数据的分析. 狼疮科学医学. 2018;5. doi: 10.1136.

15. Yeo AL, Koelmeyer R, Kandane-Rathnayake R, et al. 红斑狼疮低疾病活动状态与系统性红斑狼疮患者直接医疗费用降低相关[在线出版前发表], 2019年7月8日]. 关节炎 Care Res (Hoboken). 2020年9月,72 (9):1289 - 1295.

16. 乌鸦可. Type I interferon in the pathogenesis of 红斑狼疮. J Immunol. 2014;192(12):5459-5468.

17. Lauwerys BR, Ducreux J, Houssiau FA. I型干扰素阻断在系统性红斑狼疮中的作用:澳门第一赌城在线娱乐站在哪里? Rheumatol. 2014;53(8):1369-1376.

18. Hoffman RW, Merrill JT, Alarcón-Riquelme MM, et al. Gene expression and pharmacodynamic changes in 1,760例系统性红斑狼疮患者参加了两项用tabalumab阻断BAFF的III期试验. 关节炎Rheumatol. 2017;69(3):643-654.

19. Becker AM, Dao KH, Han BK, et al. SLE peripheral blood B cell, T细胞和骨髓细胞转录组显示出独特的特征,每个子集都有助于干扰素信号. 《澳门在线赌城娱乐》. 2013;8(6):e67003.

20. Jefferies CA. Regulating IRFs in IFN driven disease. 前面Immunol. 2019;10:325.

21 Mai L, Asaduzzaman A, Noamani B, et al. 基线干扰素信号可预测系统性红斑狼疮患者随后5年的疾病严重程度. 关节炎治疗. 2021;23:29


Veeva ID: Z4-54681
Date of preparation: May 2023